Institute of Metabolism & Integrative Biology (IMIB), Fudan University, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Front Immunol. 2021 Jun 29;12:669150. doi: 10.3389/fimmu.2021.669150. eCollection 2021.
Accumulating evidence demonstrated the crucial role of gut microbiota in many human diseases, including cancer. Checkpoint inhibitor therapy has emerged as a novel treatment and has been clinically accepted as a major therapeutic strategy for cancer. Gut microbiota is related to cancer and the effect of immune checkpoint inhibitors (ICIs), and supplement with specific bacterial species can restore or enhance the responses to the ICIs. Namely, specified bacteria can serve as the biomarkers for distinguishing the patient who will respond to ICIs and determine the effectiveness of ICIs, as well as predicting the efficacy of checkpoint inhibitor immunotherapy. Regardless of the significant findings, the relationship between gut microbiota and the effect of ICIs treatment needs a more thorough understanding to provide more effective therapeutic plans and reduce treatment complication. In this review, we summarized the role of gut microbiota played in immune system and cancer. We mainly focus on the relationship between gut microbiota and the checkpoint inhibitor immunotherapy.
越来越多的证据表明，肠道微生物群在许多人类疾病中起着关键作用，包括癌症。检查点抑制剂治疗已成为一种新的治疗方法，并已被临床接受为癌症的主要治疗策略。肠道微生物群与癌症和免疫检查点抑制剂（ICIs）的作用有关，补充特定的细菌种类可以恢复或增强对 ICIs 的反应。也就是说，特定的细菌可以作为区分对 ICI 有反应的患者的生物标志物，并确定 ICI 的有效性，以及预测检查点抑制剂免疫治疗的疗效。尽管有重要的发现，但肠道微生物群与 ICI 治疗效果之间的关系需要更深入的了解，以提供更有效的治疗方案并减少治疗并发症。在这篇综述中，我们总结了肠道微生物群在免疫系统和癌症中的作用。我们主要关注肠道微生物群与检查点抑制剂免疫治疗之间的关系。
Zotero 插件